Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Must been bas deploying more dry powder.
And we know who it wasn't.
Oh oh! Did Missling speak again somewhere?
You have said that so many times.
You would have to ask that of the folks here who felt sure Hampel would bring Anavex with him into a partnership with Easai.
“why would Anavex want to partner with Eisai”
Why would Eisai do that with Hampel knowing better, when there is Anavex?
Press release: BioArctic and Eisai sign research evaluation agreement regarding a potential new treatment combining BioArctic’s proprietary BrainTransporter™ technology with an undisclosed Alzheimer drug candidat. https://t.co/BBnMqt4FFT
— BioArcticAB (@bioarcticab) April 20, 2024
Or just more absolute nonsense from you...
Maybe even delusions too.
Yes automated analysis of MRI volumetric scan images are validated, but not equally reliable for all parts of the brain. I doubt a comparison between human expert and automated image analysis would fall out to the advantage of a manual expert approach. It would also be a very expensive test to establish given that those experts are likely spending their time and efforts in the clinic where needed and as they should.
I might be adding too, but not in any FOMO hurry 😉
Yes and if those volumetric results correlates to other biomarkers and clinical outcomes, as Missling indicates, it should change the outlook.
As always I want the opportunity to scrutinise the information before getting too excited.
That is correct.
The P2b/3 MRI brain region volumetric biomarker top level results Anavex have published so far are encouraging and I'm looking forward to more detail on that, the data overall and correlations between all the various measures, when presented or published hopefully soon'ish.
Meanwhile, this recent paper and table 1 gives some insights into the reliability of automatically establishing volumetrics across different brain regions by comparing two such software applications, one of which is FDA certified: Reliability of automated brain volumetric analysis: A test by comparing NeuroQuant and volBrain software
Fortunately we have you to remember to add that - well done! You can have a biscuit.
That’s fine.
The point is to weigh up as an investor individual appetite for risk, because risk there is in being caught up in FOMO!
Indeed Missling is the FOMO master and it is becoming clearer from every presentation he makes. He has clearly snared, possibly beyond means, some here. Is his straight face really straight? Could be with some non-zero chance worth a well considered can afford to lose dip.
Ohsay is as original as ever and obviously talented, I just don’t know at what.
Yeah they are not paying me or providing the script these days.
Aliens and cowboys is another possibility.
Who is manipulating the manipulators?
Easy to call a $AVXL bottom, there is a new one every trading day and especially on days where Missling speaks.
Or just deploy more of the endless reserves of ever more dry powder?
That’s like saying just approve it without the approval process be cause the CHMP has accepted that the application is worthy of going through the approval process.
If that makes sense to you then it explains a few things about the WGT mind.
You haven’t responded in reasoned way to the reasoned explanations that you have received.
I don’t exclude that no MAA will be filed, but more a question of when. To me it is more likely Anavex could fail to respond satisfactorily to clock stop 1 requests, simply because the P2b/3 results are not good enough once scrutinised by CHMP.
I see. My basic curiosity is more centred on seeing an MAA filed, validated and then a succesful response from Anavex to the EMA process clock-stop 1 requests.
Not much point in caring too much about a dose finding small P2 trial just now, imo.
At least we have you recognising that, some progress for this mb.
I guess you were then just excited that Missling was consistently making catalyst statements that he can go on to break as usual.
So no new information then, same old - got it!
Either there is something wrong with what they seek,
Are you asking that because you hope the schizo trial will save your $AVXL investment?
In reality we have likely been looking at the 9/10 of the iceberg under the waterline full of debris and dirt with many thinking, and apparently some still do, that it was the beautifully clear 1/10 above water that MJFF thought they were supportting 5 years ago.
Some people are afraid of that they don't understand. Others just make an effort to understand with an open and objective mind driven by curiosity to reach a rational conclusion.
Now isn’t that strange given Hoskuld’s always measured view on the chances of a slam dunk Excellence trial readout.
Just and for the avoidance of doubt /sarc flag applies!
Anavex have only a Strategic AI Partnership, which isn't doing anything as far we can tell.
https://www.anavex.com/post/anavex-life-sciences-and-partex-group-announce-strategic-partnership
That btw. is pretty positive, but I guess the emoji warriors don't really get that either.
As I have explained, we need to wait until 13th May. Motions for lead plaintiff customarily comes just before the deadline. Great if none do, also as I have said, because then the judge will dismiss the case as per the granted motion filed by the Anavex law firm.
See last docket; https://www.courtlistener.com/docket/68337947/blum-v-anavex-life-sciences-corporation/
Peace with that.
I am holding cheaper shares too and the profit taken over the years from trading every irrational $AVXL price spike will never be lost - at least not for me in Anavex.
There is a non-zero chance of approval from currently complete trials. The odds can be adjusted as new information comes to hand.
Nothing is certain but death and taxes, especially true when it comes to Missling and his catalysts!
I’ll keep my ‘wait even longer and see’ hat on!
AF seems to like a clear positive clinical trial readout.
$ITCI
— Adam Feuerstein ✡️ (@adamfeuerstein) April 16, 2024
Lumateperone 42 mg met the primary endpoint of change from baseline at Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo (4.9 point reduction v. placebo; p<0.0001; Cohen’s d effect size (ES)= 0.61)
You will receive your invitation once Missling is back from his mindfulness yoga retreat prepared and focused enough to face the public and the question from perhaps one analyst. Even Bishop doesn't show up anyone more.